Category: Cancer Treatments

Home / Cancer Treatments

Categories

Effectiveness of CAR T-Cell therapy against high risk large B-Cell lymphoma

Dec 2020: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-l...

CAR T-Cell therapy for childhood brain tumor

Dec 2021: CAR T-Cell therapy is currently approved for some forms of leukemia, lymphoma, and multiple myeloma. Researchers have now also developed the corresponding GD2 CAR T-cell therapy for the trea...

Patient in China achieves complete remission from leukemia after CAR T-Cell therapy

Feb 2022: In China, a patient whose life was on the verge of ending was entirely healed of leukaemia thanks to CAR T-cell therapy, which stimulated the immune system. All cancer cells vanished swiftly...

China-based CAR-T Cell therapy achieves breakthrough clinical trial results

June 2016: Professor Huang He of Zhejiang University's First Affiliated Hospital presented the outcomes of 10 clinical cases, including CAR-T cell therapy for leukaemia treatment, at the 2016 Haemato...

CAR T-Cell therapy saves leukemia patient in China

Feb 2022: A 12-year-old girl from southwest China's Chongqing Municipality was saved by an unconventional therapy instead of chemotherapy or hematopoietic stem cell transplantation. Yi Mengdie has ...

Ruxolitinib is approved for chronic graft-versus-host disease

October 2021: After failure of one or two lines of systemic therapy, the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte Corp.) for chronic graft-versus-host disease (cGVHD) in adult...

Tisotumab forvedotin-tftv is approved for recurrent or metastatic cervical cancer

October 2021: The FDA has given tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor combination, rapid approval for adult patients with recurrent ...

The FDA has approved belumosudil for the treatment of chronic graft-versus-host disease

August 2021: After failure of at least two prior lines of systemic therapy, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult...

The FDA has approved idecabtagene vicleucel for the treatment of multiple myeloma

August 2021: The Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed or refractory multiple myeloma after four...

Beta Thalassemia and its consideration with COVID-19

July 2021: Beta-thalassemia is an inherited condition caused by mutations in a gene involved in the production of a component of haemoglobin, the protein that transports oxygen throughout the body. Th...

Scan the code